meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
ipilimumab plus gp100
ipilimumab plus SoC
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (2mg/kg)
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Immunostimulant
vs vaccine
vs gp100
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
PD-L1 < 5%
PD-L1 > 5%
stage M1A
stage M1B
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritic rash TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
deaths (OS)
mML - L2 - all population
metastatic/adv melanoma (mML)
mML - 2nd line (L2)
mML - L2 - all population
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC)
1
certainty unassessable
-5%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open